298 related articles for article (PubMed ID: 24843883)
1. Epigenetic dysregulation in glioma.
Kondo Y; Katsushima K; Ohka F; Natsume A; Shinjo K
Cancer Sci; 2014 Apr; 105(4):363-9. PubMed ID: 24843883
[TBL] [Abstract][Full Text] [Related]
2. Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective.
Tsankova NM; Canoll P
J Neurooncol; 2014 Sep; 119(3):481-90. PubMed ID: 24962200
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNAs in brain tumours: Focus on recent epigenetic findings in glioma.
Pop S; Enciu AM; Necula LG; Tanase C
J Cell Mol Med; 2018 Oct; 22(10):4597-4610. PubMed ID: 30117678
[TBL] [Abstract][Full Text] [Related]
4. Epigenomic Reprogramming as a Driver of Malignant Glioma.
Phillips RE; Soshnev AA; Allis CD
Cancer Cell; 2020 Nov; 38(5):647-660. PubMed ID: 32916125
[TBL] [Abstract][Full Text] [Related]
5. The epigenetic dysfunction underlying malignant glioma pathogenesis.
Dharmaiah S; Huse JT
Lab Invest; 2022 Jul; 102(7):682-690. PubMed ID: 35152274
[TBL] [Abstract][Full Text] [Related]
6. Investigational new drugs for brain cancer.
Staedtke V; Bai RY; Laterra J
Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
[TBL] [Abstract][Full Text] [Related]
7. Molecular biology of glioma.
Marumoto T; Saya H
Adv Exp Med Biol; 2012; 746():2-11. PubMed ID: 22639155
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states.
Chaligne R; Gaiti F; Silverbush D; Schiffman JS; Weisman HR; Kluegel L; Gritsch S; Deochand SD; Gonzalez Castro LN; Richman AR; Klughammer J; Biancalani T; Muus C; Sheridan C; Alonso A; Izzo F; Park J; Rozenblatt-Rosen O; Regev A; Suvà ML; Landau DA
Nat Genet; 2021 Oct; 53(10):1469-1479. PubMed ID: 34594037
[TBL] [Abstract][Full Text] [Related]
9. Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses.
Ciechomska IA; Jayaprakash C; Maleszewska M; Kaminska B
Adv Exp Med Biol; 2020; 1202():259-279. PubMed ID: 32034718
[TBL] [Abstract][Full Text] [Related]
10. Impact of epigenetic reprogramming on antitumor immune responses in glioma.
McClellan BL; Haase S; Nunez FJ; Alghamri MS; Dabaja AA; Lowenstein PR; Castro MG
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647827
[TBL] [Abstract][Full Text] [Related]
11. Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.
Malzkorn B; Wolter M; Riemenschneider MJ; Reifenberger G
Brain Pathol; 2011 Nov; 21(6):619-32. PubMed ID: 21939466
[TBL] [Abstract][Full Text] [Related]
12. Developmental origins and oncogenic pathways in malignant brain tumors.
Lu QR; Qian L; Zhou X
Wiley Interdiscip Rev Dev Biol; 2019 Jul; 8(4):e342. PubMed ID: 30945456
[TBL] [Abstract][Full Text] [Related]
13. [The epigenetic mechanisms at work in pediatric gliomas].
Larsen CJ
Bull Cancer; 2014 Apr; 101(4):341. PubMed ID: 24918236
[No Abstract] [Full Text] [Related]
14. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
15. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
16. New advances of microRNAs in glioma stem cells, with special emphasis on aberrant methylation of microRNAs.
Zhao B; Bian EB; Li J; Li J
J Cell Physiol; 2014 Sep; 229(9):1141-7. PubMed ID: 24374932
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiles of glioma.
Brennan C
Curr Neurol Neurosci Rep; 2011 Jun; 11(3):291-7. PubMed ID: 21465149
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells.
Waha A; Felsberg J; Hartmann W; von dem Knesebeck A; Mikeska T; Joos S; Wolter M; Koch A; Yan PS; Endl E; Wiestler OD; Reifenberger G; Pietsch T; Waha A
Cancer Res; 2010 Feb; 70(4):1689-99. PubMed ID: 20124482
[TBL] [Abstract][Full Text] [Related]
20. Pediatric gliomas as neurodevelopmental disorders.
Baker SJ; Ellison DW; Gutmann DH
Glia; 2016 Jun; 64(6):879-95. PubMed ID: 26638183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
